1110002N22Rik Inhibitors
Chemical inhibitors of the protein 1110002N22Rik act by interfering with specific signaling pathways that are essential for the protein's function. LY294002 and Wortmannin are two such inhibitors that target the PI3K/Akt signaling pathway. LY294002 achieves this by inhibiting PI3K, preventing the subsequent activation of Akt, which is crucial for the protein's activity. Wortmannin operates similarly by covalently binding to PI3K, ensuring that the PI3K/Akt pathway is suppressed, and thus, the function of 1110002N22Rik is inhibited due to the lack of necessary Akt signaling.
Another set of inhibitors, PD98059 and U0126, disrupt the MAPK/ERK pathway, which could be upstream of 1110002N22Rik. They inhibit MEK1/2, blocking the phosphorylation and activation of ERK. If 1110002N22Rik relies on ERK for activation, these inhibitors would prevent its function. Similarly, SB203580 specifically targets p38 MAPK, and if 1110002N22Rik operates downstream of p38 MAPK, this inhibitor would halt any p38-mediated activation of the protein. Inhibition of JNK by SP600125 would directly impact 1110002N22Rik if it is a substrate for JNK, halting JNK-mediated phosphorylation. Rapamycin, targeting mTOR, would also inhibit 1110002N22Rik if its activity is contingent on mTOR signaling. Src family kinases, which could phosphorylate 1110002N22Rik, are inhibited by PP2 and Dasatinib, precluding activation of the protein by these kinases. Lastly, EGFR tyrosine kinase inhibitors such as Gefitinib, Erlotinib, and Lapatinib interrupt the EGFR/HER2 signaling pathways, which would directly inhibit 1110002N22Rik if it is activated through these routes, by blocking phosphorylation events necessary for its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K which is involved in the Akt signaling pathway. Since 1110002N22Rik is known to be part of the PI3K/Akt pathway, inhibition of PI3K by LY294002 will prevent Akt activation, thereby directly inhibiting 1110002N22Rik activity when it requires Akt for its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A covalent inhibitor of PI3K, leading to the suppression of the PI3K/Akt pathway. Wortmannin's action results in the direct inhibition of 1110002N22Rik by preventing its downstream signaling via Akt if 1110002N22Rik is an Akt substrate. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK1/2 in the MAPK/ERK pathway. By blocking the phosphorylation and activation of ERK, PD98059 would directly inhibit 1110002N22Rik if it is regulated by ERK-mediated phosphorylation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Selectively inhibits MEK1/2, thereby blocking ERK pathway activation. If 1110002N22Rik is downstream of ERK in its signaling pathway, U0126 would directly inhibit the protein's function by preventing its phosphorylation by ERK. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective inhibitor of p38 MAPK. Direct inhibition of 1110002N22Rik by SB203580 would occur if 1110002N22Rik functions downstream of p38 MAPK, as it would block the necessary p38-mediated phosphorylation events. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which if 1110002N22Rik is a substrate for JNK, would result in direct inhibition of the protein by blocking JNK-mediated phosphorylation necessary for 1110002N22Rik's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, which could directly inhibit 1110002N22Rik if it is an mTOR pathway-dependent protein, by blocking the necessary mTOR-mediated phosphorylation events that activate 1110002N22Rik. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src family kinase inhibitor. As Src kinases can phosphorylate a variety of substrates, if 1110002N22Rik requires Src kinase activity for its function, PP2 would directly inhibit the protein by preventing this phosphorylation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits Src family kinases and BCR-ABL. Dasatinib would directly inhibit 1110002N22Rik function by preventing phosphorylation by Src if 1110002N22Rik activity is dependent on Src kinase signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Inhibits EGFR tyrosine kinase, leading to the inhibition of the downstream MAPK pathway. Gefitinib would directly inhibit 1110002N22Rik if it functions downstream of EGFR, by preventing activation through this pathway. | ||||||